Intrinsic value of Radius Health, Inc. - RDUS

Previous Close

$23.91

  Intrinsic Value

$0.29

stock screener

  Rating & Target

str. sell

-99%

Previous close

$23.91

 
Intrinsic value

$0.29

 
Up/down potential

-99%

 
Rating

str. sell

We calculate the intrinsic value of RDUS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  158
  245
  366
  531
  749
  1,030
  1,383
  1,815
  2,336
  2,950
  3,664
  4,479
  5,399
  6,424
  7,553
  8,786
  10,121
  11,556
  13,087
  14,714
  16,434
  18,244
  20,145
  22,134
  24,212
  26,378
  28,635
  30,982
  33,423
  35,960
Variable operating expenses, $m
  388
  600
  897
  1,301
  1,835
  2,522
  3,385
  4,445
  5,719
  7,223
  8,969
  10,965
  13,217
  15,725
  18,490
  21,509
  24,776
  28,288
  32,037
  36,019
  40,229
  44,661
  49,313
  54,183
  59,269
  64,573
  70,096
  75,842
  81,818
  88,028
Fixed operating expenses, $m
  227
  232
  237
  242
  248
  253
  259
  264
  270
  276
  282
  288
  295
  301
  308
  314
  321
  328
  336
  343
  351
  358
  366
  374
  382
  391
  400
  408
  417
  426
Total operating expenses, $m
  615
  832
  1,134
  1,543
  2,083
  2,775
  3,644
  4,709
  5,989
  7,499
  9,251
  11,253
  13,512
  16,026
  18,798
  21,823
  25,097
  28,616
  32,373
  36,362
  40,580
  45,019
  49,679
  54,557
  59,651
  64,964
  70,496
  76,250
  82,235
  88,454
Operating income, $m
  -457
  -587
  -768
  -1,012
  -1,333
  -1,745
  -2,261
  -2,893
  -3,653
  -4,549
  -5,587
  -6,774
  -8,112
  -9,603
  -11,245
  -13,037
  -14,976
  -17,060
  -19,285
  -21,648
  -24,146
  -26,775
  -29,535
  -32,423
  -35,440
  -38,585
  -41,861
  -45,268
  -48,812
  -52,494
EBITDA, $m
  -453
  -582
  -760
  -1,001
  -1,319
  -1,726
  -2,235
  -2,860
  -3,610
  -4,494
  -5,520
  -6,693
  -8,014
  -9,486
  -11,107
  -12,877
  -14,792
  -16,850
  -19,047
  -21,380
  -23,846
  -26,443
  -29,168
  -32,020
  -34,999
  -38,105
  -41,339
  -44,705
  -48,203
  -51,840
Interest expense (income), $m
  0
  24
  12
  22
  36
  56
  81
  114
  155
  205
  266
  338
  421
  516
  623
  743
  874
  1,018
  1,173
  1,341
  1,519
  1,709
  1,909
  2,120
  2,342
  2,574
  2,816
  3,068
  3,331
  3,605
  3,889
Earnings before tax, $m
  -481
  -599
  -790
  -1,048
  -1,389
  -1,826
  -2,375
  -3,048
  -3,858
  -4,815
  -5,925
  -7,195
  -8,628
  -10,226
  -11,987
  -13,911
  -15,994
  -18,234
  -20,626
  -23,167
  -25,854
  -28,684
  -31,655
  -34,765
  -38,013
  -41,401
  -44,929
  -48,600
  -52,417
  -56,384
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -481
  -599
  -790
  -1,048
  -1,389
  -1,826
  -2,375
  -3,048
  -3,858
  -4,815
  -5,925
  -7,195
  -8,628
  -10,226
  -11,987
  -13,911
  -15,994
  -18,234
  -20,626
  -23,167
  -25,854
  -28,684
  -31,655
  -34,765
  -38,013
  -41,401
  -44,929
  -48,600
  -52,417
  -56,384

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  154
  238
  356
  517
  730
  1,003
  1,346
  1,768
  2,275
  2,873
  3,568
  4,362
  5,257
  6,255
  7,355
  8,555
  9,855
  11,252
  12,743
  14,327
  16,002
  17,765
  19,615
  21,552
  23,575
  25,685
  27,882
  30,168
  32,544
  35,015
Adjusted assets (=assets-cash), $m
  154
  238
  356
  517
  730
  1,003
  1,346
  1,768
  2,275
  2,873
  3,568
  4,362
  5,257
  6,255
  7,355
  8,555
  9,855
  11,252
  12,743
  14,327
  16,002
  17,765
  19,615
  21,552
  23,575
  25,685
  27,882
  30,168
  32,544
  35,015
Revenue / Adjusted assets
  1.026
  1.029
  1.028
  1.027
  1.026
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
  1.027
Average production assets, $m
  14
  22
  33
  48
  68
  94
  126
  165
  213
  268
  333
  408
  491
  585
  687
  800
  921
  1,052
  1,191
  1,339
  1,495
  1,660
  1,833
  2,014
  2,203
  2,400
  2,606
  2,819
  3,042
  3,272
Working capital, $m
  -13
  -21
  -31
  -45
  -64
  -88
  -118
  -154
  -199
  -251
  -311
  -381
  -459
  -546
  -642
  -747
  -860
  -982
  -1,112
  -1,251
  -1,397
  -1,551
  -1,712
  -1,881
  -2,058
  -2,242
  -2,434
  -2,633
  -2,841
  -3,057
Total debt, $m
  92
  168
  274
  419
  610
  856
  1,165
  1,544
  2,001
  2,539
  3,164
  3,879
  4,685
  5,583
  6,573
  7,653
  8,823
  10,080
  11,423
  12,848
  14,355
  15,942
  17,607
  19,350
  21,171
  23,070
  25,047
  27,104
  29,244
  31,467
Total liabilities, $m
  139
  214
  321
  465
  657
  903
  1,212
  1,591
  2,047
  2,586
  3,211
  3,925
  4,732
  5,630
  6,619
  7,700
  8,870
  10,127
  11,469
  12,895
  14,402
  15,988
  17,654
  19,397
  21,218
  23,116
  25,094
  27,151
  29,290
  31,513
Total equity, $m
  15
  24
  36
  52
  73
  100
  135
  177
  227
  287
  357
  436
  526
  626
  735
  856
  986
  1,125
  1,274
  1,433
  1,600
  1,776
  1,962
  2,155
  2,358
  2,568
  2,788
  3,017
  3,254
  3,501
Total liabilities and equity, $m
  154
  238
  357
  517
  730
  1,003
  1,347
  1,768
  2,274
  2,873
  3,568
  4,361
  5,258
  6,256
  7,354
  8,556
  9,856
  11,252
  12,743
  14,328
  16,002
  17,764
  19,616
  21,552
  23,576
  25,684
  27,882
  30,168
  32,544
  35,014
Debt-to-equity ratio
  5.980
  7.050
  7.690
  8.100
  8.360
  8.540
  8.650
  8.740
  8.800
  8.840
  8.870
  8.890
  8.910
  8.930
  8.940
  8.950
  8.950
  8.960
  8.960
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.980
  8.980
  8.990
  8.990
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -481
  -599
  -790
  -1,048
  -1,389
  -1,826
  -2,375
  -3,048
  -3,858
  -4,815
  -5,925
  -7,195
  -8,628
  -10,226
  -11,987
  -13,911
  -15,994
  -18,234
  -20,626
  -23,167
  -25,854
  -28,684
  -31,655
  -34,765
  -38,013
  -41,401
  -44,929
  -48,600
  -52,417
  -56,384
Depreciation, amort., depletion, $m
  4
  5
  7
  10
  14
  19
  26
  34
  43
  54
  67
  82
  98
  117
  137
  160
  184
  210
  238
  268
  299
  332
  367
  403
  441
  480
  521
  564
  608
  654
Funds from operations, $m
  -477
  -594
  -783
  -1,038
  -1,374
  -1,807
  -2,349
  -3,015
  -3,815
  -4,760
  -5,858
  -7,113
  -8,530
  -10,109
  -11,850
  -13,751
  -15,810
  -18,023
  -20,388
  -22,900
  -25,555
  -28,352
  -31,288
  -34,362
  -37,572
  -40,921
  -44,408
  -48,036
  -51,808
  -55,729
Change in working capital, $m
  -5
  -7
  -10
  -14
  -19
  -24
  -30
  -37
  -44
  -52
  -61
  -69
  -78
  -87
  -96
  -105
  -113
  -122
  -130
  -138
  -146
  -154
  -162
  -169
  -177
  -184
  -192
  -200
  -207
  -216
Cash from operations, $m
  -472
  -587
  -772
  -1,024
  -1,356
  -1,783
  -2,319
  -2,978
  -3,771
  -4,708
  -5,797
  -7,044
  -8,452
  -10,022
  -11,754
  -13,646
  -15,697
  -17,902
  -20,258
  -22,761
  -25,409
  -28,198
  -31,127
  -34,193
  -37,396
  -40,737
  -44,216
  -47,836
  -51,601
  -55,514
Maintenance CAPEX, $m
  -2
  -3
  -4
  -7
  -10
  -14
  -19
  -25
  -33
  -43
  -54
  -67
  -82
  -98
  -117
  -137
  -160
  -184
  -210
  -238
  -268
  -299
  -332
  -367
  -403
  -441
  -480
  -521
  -564
  -608
New CAPEX, $m
  -5
  -8
  -11
  -15
  -20
  -26
  -32
  -39
  -47
  -56
  -65
  -74
  -84
  -93
  -103
  -112
  -121
  -131
  -139
  -148
  -156
  -165
  -173
  -181
  -189
  -197
  -205
  -214
  -222
  -231
Cash from investing activities, $m
  -7
  -11
  -15
  -22
  -30
  -40
  -51
  -64
  -80
  -99
  -119
  -141
  -166
  -191
  -220
  -249
  -281
  -315
  -349
  -386
  -424
  -464
  -505
  -548
  -592
  -638
  -685
  -735
  -786
  -839
Free cash flow, $m
  -479
  -597
  -788
  -1,046
  -1,385
  -1,822
  -2,370
  -3,042
  -3,851
  -4,807
  -5,916
  -7,185
  -8,617
  -10,213
  -11,973
  -13,896
  -15,978
  -18,216
  -20,607
  -23,148
  -25,833
  -28,662
  -31,632
  -34,740
  -37,988
  -41,374
  -44,901
  -48,571
  -52,387
  -56,353
Issuance/(repayment) of debt, $m
  -88
  76
  106
  145
  191
  246
  309
  379
  456
  539
  625
  715
  806
  898
  990
  1,081
  1,170
  1,257
  1,342
  1,426
  1,507
  1,587
  1,665
  1,743
  1,821
  1,899
  1,977
  2,057
  2,139
  2,223
Issuance/(repurchase) of shares, $m
  626
  608
  802
  1,064
  1,410
  1,853
  2,409
  3,091
  3,909
  4,875
  5,994
  7,274
  8,718
  10,325
  12,097
  14,031
  16,124
  18,373
  20,775
  23,326
  26,022
  28,861
  31,840
  34,958
  38,215
  41,612
  45,149
  48,828
  52,654
  56,631
Cash from financing (excl. dividends), $m  
  538
  684
  908
  1,209
  1,601
  2,099
  2,718
  3,470
  4,365
  5,414
  6,619
  7,989
  9,524
  11,223
  13,087
  15,112
  17,294
  19,630
  22,117
  24,752
  27,529
  30,448
  33,505
  36,701
  40,036
  43,511
  47,126
  50,885
  54,793
  58,854
Total cash flow (excl. dividends), $m
  59
  86
  120
  163
  216
  278
  348
  427
  514
  607
  703
  804
  907
  1,010
  1,114
  1,216
  1,316
  1,414
  1,510
  1,604
  1,695
  1,785
  1,874
  1,961
  2,048
  2,136
  2,225
  2,314
  2,407
  2,501
Retained Cash Flow (-), $m
  -626
  -608
  -802
  -1,064
  -1,410
  -1,853
  -2,409
  -3,091
  -3,909
  -4,875
  -5,994
  -7,274
  -8,718
  -10,325
  -12,097
  -14,031
  -16,124
  -18,373
  -20,775
  -23,326
  -26,022
  -28,861
  -31,840
  -34,958
  -38,215
  -41,612
  -45,149
  -48,828
  -52,654
  -56,631
Prev. year cash balance distribution, $m
  191
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -376
  -522
  -681
  -901
  -1,194
  -1,576
  -2,061
  -2,663
  -3,395
  -4,268
  -5,291
  -6,470
  -7,811
  -9,315
  -10,984
  -12,815
  -14,808
  -16,959
  -19,265
  -21,722
  -24,326
  -27,075
  -29,966
  -32,997
  -36,167
  -39,476
  -42,924
  -46,514
  -50,248
  -54,129
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -361
  -478
  -593
  -742
  -926
  -1,144
  -1,392
  -1,665
  -1,950
  -2,238
  -2,513
  -2,761
  -2,970
  -3,127
  -3,225
  -3,257
  -3,222
  -3,123
  -2,966
  -2,760
  -2,516
  -2,247
  -1,964
  -1,681
  -1,407
  -1,152
  -921
  -720
  -549
  -408
Current shareholders' claim on cash, %
  50.0
  10.1
  2.3
  0.6
  0.2
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.

FINANCIAL RATIOS  of  Radius Health, Inc. (RDUS)

Valuation Ratios
P/E Ratio -5.6
Price to Sales 0
Price to Book 3.4
Price to Tangible Book
Price to Cash Flow -7.4
Price to Free Cash Flow -7.2
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 200%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -44.5%
Ret/ On Assets - 3 Yr. Avg. -59.3%
Return On Total Capital -47.7%
Ret/ On T. Cap. - 3 Yr. Avg. -83.4%
Return On Equity -47.7%
Return On Equity - 3 Yr. Avg. -137.6%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 0%
EBITDA Margin - 3 Yr. Avg. 0%
Operating Margin 0%
Oper. Margin - 3 Yr. Avg. 0%
Pre-Tax Margin 0%
Pre-Tax Margin - 3 Yr. Avg. 0%
Net Profit Margin 0%
Net Profit Margin - 3 Yr. Avg. 0%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

RDUS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the RDUS stock intrinsic value calculation we used $99 million for the last fiscal year's total revenue generated by Radius Health, Inc.. The default revenue input number comes from 0001 income statement of Radius Health, Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our RDUS stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for RDUS is calculated based on our internal credit rating of Radius Health, Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Radius Health, Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of RDUS stock the variable cost ratio is equal to 245.5%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $222 million in the base year in the intrinsic value calculation for RDUS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 13.3% for Radius Health, Inc..

Corporate tax rate of 27% is the nominal tax rate for Radius Health, Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the RDUS stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for RDUS are equal to 9.1%.

Life of production assets of 4.5 years is the average useful life of capital assets used in Radius Health, Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for RDUS is equal to -8.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $60.632 million for Radius Health, Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 45.750 million for Radius Health, Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Radius Health, Inc. at the current share price and the inputted number of shares is $1.1 billion.

RELATED COMPANIES Price Int.Val. Rating
LLY Eli Lilly and 115.49 89.42  sell
AMGN Amgen Inc. 187.11 157.83  hold
FLXN Flexion Therap 11.64 0.72  str.sell
MRK Merck & Compan 84.57 44.01  sell

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.